Treatment for Substance Use Disorder With Co-Occurring Mental Illness
Open accessThe DOI matches its Crossref record; 168 of the 169 references it cites were found in a registry or an index.
Abstract
Substance use disorder is a highly prevalent condition, leading to significant morbidity, mortality, and burden on the health care system. Substance use disorders are overrepresented among individuals with a mental illness. The term "dual diagnosis" was introduced by the World Health Organization in the mid-1990s and refers to the co-occurrence of a substance use disorder with mental illness-a more recently used term is "co-occurring disorders." In the past decade, substantial progress has been made toward expanding psychotherapeutic and pharmacotherapeutic treatments for treating co-occurring disorders. Yet management remains a challenge among clinicians and has been a source of confusion and considerable controversy. This review describes the epidemiology and treatment of co-occurring disorders, with a focus on major depressive disorder, anxiety disorders, and attention-deficit hyperactivity disorder. Substance use may make diagnosis of the underlying psychiatric condition difficult, and a period of abstinence may be necessary. Findings from efficacy studies of medications used to treat co-occurring disorders are reviewed, as are results of preliminary studies of newer treatments, such as topiramate, ketamine, noninvasive brain stimulation, and deep brain stimulation. Treatment recommendations that combine medications and psychosocial interventions are summarized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Posttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Deep Brain Stimulation for Treatment-Resistant Depression
Mayberg, H. S., Lozano, A. M., Voon, V., McNeely, H. E., Seminowicz, D., Hamani, C., Schwalb, J. M., & Kennedy, S. H. (2005) · Neuron · doi:10.1016/j.neuron.2005.02.014 · Cited by 4,059
Regier, D. A. (1990) · JAMA · doi:10.1001/jama.1990.03450190043026 · Cited by 3,962
Bardo, M. T., & Hammer, R. P. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90226-e · Cited by 3,219
Kessler, R. C., Petukhova, M., Sampson, N. A., Zaslavsky, A. M., & Wittchen, H. (2012) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.1359 · Cited by 2,947
Research works printed but not linked: 6
- Centers for Disease Control and Prevention (CDC), 2010, Morb Mortal Wkly Rep, 59, 1229
- Hasin DS, 1998, Drug Alcohol Depend, 39, 197
- 10.1111/j.1530-0277.2000.tb04648.x · doi:10.1111/j.1530-0277.2000.tb04648.x · Paper page
- 10.1037/0893-164X.7.4.211 · DOI · Paper page
- Niciu MJ, 2014, Int J Neuropsychopharmacol, 18, pyu039
- Rapinesi C, 2013, Prim Care Companion CNS Disord, 15, PCC.12m01438
Cited by
Bahji, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040999 · Cited by 83
“Pharmacological interventions play a pivotal role in the treatment of SUDs and psychiatric conditions [22].”
BackgroundLevitt, E. E., Syan, S. K., Sousa, S., Costello, M. J., Rush, B., Samokhvalov, A. V., McCabe, R. E., Kelly, J., & MacKillop, J. (2021) · Addictive Behaviors · doi:10.1016/j.addbeh.2020.106649 · Cited by 35
Emerging strategies and clinical recommendations for the management of novel depression subtypes
Chiappini, S., Sampogna, G., Ventriglio, A., Menculini, G., Ricci, V., Pettorruso, M., Volpe, U., & Martinotti, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2470973 · Cited by 24
Icick, R., Moggi, F., Slobodin, O., Dom, G., Matthys, F., van den Brink, W., LEVIN, F. R., Blankers, M., Kaye, S. S., Demetrovics, Z., et al. (2020) · European Addiction Research · doi:10.1159/000508546 · Cited by 28
Self-citationBarriers to retention in substance use treatment: Validation of a new, theory-based scale
Zemore, S. E., Ware, O. D., Gilbert, P. A., & Pinedo, M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108422 · Cited by 21
Díaz-Fernández, S., Miranda, J. J. F., Pastor, F. S. P., & Lopez-Munoz, F. J. (2023) · Archives of Women s Mental Health · doi:10.1007/s00737-023-01353-w · Cited by 26
Psychotherapies in opioid use disorder: toward a step-care model
Durpoix, A., Rolling, J., Coutelle, R., & Lalanne, L. (2023) · Journal of Neural Transmission · doi:10.1007/s00702-023-02720-8 · Cited by 22
“In case of a dual diagnosis, CBT acts on both addictions and comorbid psychiatric disorders (Iqbal et al. 2019; Lees et al. 2021; Roberts et al. 2022).”
BackgroundTorrens, M., Tirado-Muñoz, J., Fonseca, F., Farré, M., González-Pinto, A. M., Arrojo, M., Bernardo, M., Arranz, B., Garriga, M., Sáiz, P. A., et al. (2021) · Adicciones · doi:10.20882/adicciones.1559 · Cited by 27
Watkins, K. E., Hunter, S. B., Cohen, C. C., Leamon, I. M., Hurley, B., McCreary, M. P., & Ober, A. J. (2021) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-020-01103-5 · Cited by 16
Psychiatric comorbidity in substance use disorders, a systematic review of neuro-imaging findings
Tesselaar, D. R. M., Schellekens, A., Homberg, J. R., Booij, J., & Guerrin, C. G. J. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106325 · Cited by 22
Kearney-Ramos, T. E., & Haney, M. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110290 · Cited by 12
Chiappini, S., Mosca, A., Semeraro, F., Amerio, A., Berardelli, I., Cremaschi, L., Bernardo, I. D., Pettorruso, M., Serafini, G., Dell’Osso, B. M., et al. (2025) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2025.152616 · Cited by 15
Dinwiddie, A. T., Gupta, S., Mattson, C. L., O’Donnell, J. K., & Seth, P. (2024) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7334a3 · Cited by 10
“Force (USPSTF) recommendations for adults in primary care settings, §§§ and the need to link and integrate treatments to prevent overdose and improve mental health ( 2 ).”
Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002268 · Cited by 13
“11 However, despite the establishment of an appropriate treatment paradigm with current antidepressants, up to 60% of patients with OCD continue to experience debilitating residual symptoms, 9 and less than 30% of patients with PTSD achieve clinical remission.”
Navigating Evidence, Challenges, and Caution in the Treatment of Stimulant Use Disorders
Bahji, A., Danilewitz, M., & Crockford, D. (2023) · Brain Sciences · doi:10.3390/brainsci13101416 · Cited by 9
“However, some have suggested that tolerance to stimulants necessitates higher doses of prescribed psychostimulants to be effective [42,43].”
BackgroundSáiz, P. A., Flórez, G., Arrojo, M., Bernardo, M., González-Pinto, A. M., Goikolea, J. M., Zorrilla, E. P., Cunill, R., Cervelló, X. C., Becoña, E., et al. (2021) · Adicciones · doi:10.20882/adicciones.1548 · Cited by 74
Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders
Castillo, C. E. C., Medellín‐Garibay, S. E., Milán‐Segovia, R. D. C., Guzmán, S. Z., Jung-Cook, H. H., Orocio-Contreras, M., & Moreno, S. R. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2457 · Cited by 8
Miranda, J. J. F., Pastor, F. S. P., Díaz-Fernández, S., Navarro, D., & Manzanares, J. (2022) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-022-00989-6 · Cited by 8
“No drugs are contraindicated (Arias Horcajadas et al., 2020; Azorin et al., 2016; Grau-Lopez et al., 2014; Iqbal et al., 2019; Murthy et al., 2019).”
InfluentialGender Differences in Depression and Quality of Life in Current and Abstinent Ketamine Users
Wang, P., Yen, C., Wu, H., Hsu, C., & Yang, Y.-Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18189567 · Cited by 7
“Furthermore, the SSRI remains the first choice for them [46].”
BackgroundPsychiatric and substance use disorders in a predominately low-income, black sample in early midlife
Mondi, C. F., Giovanelli, A., Ou, S., & Reynolds, A. J. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.02.008 · Cited by 7
Foley, C., Allan, J., Lappin, J., Courtney, R. J., Farnbach, S., Aiken, A., & Shakeshaft, A. P. (2023) · Healthcare · doi:10.3390/healthcare11121786 · Cited by 7
Ware, O. D., Ellis, J. D., Strain, E. C., Antoine, D. G., Martinez, S., & Bergeria, C. L. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.111022 · Cited by 6
Utilization of Psychotropic Medications and Polypharmacy Among Adults in Jazan Region, Saudi Arabia
Meraya, A. M., Alwhaibi, M., Syed, M. H., Shwihi, A., Mashraqi, M., Tripathi, R., Buayti, Y., & Moraya, D. (2020) · INDONESIAN JOURNAL OF PHARMACY · doi:10.22146/ijp.813 · Cited by 8
Xu, C. D., Acevedo, P., Wang, L., Wang, N., Ozuna, K., Shafique, S., Karithara, A., Padilla, V., Mao, C., Xie, X., et al. (2023) · Brain Sciences · doi:10.3390/brainsci13040661 · Cited by 8
Recent/Childhood Adversities and Mental Disorders Among US Immigrants
Cano, M. N., & Takeuchi, D. T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.573410 · Cited by 9
“A vast body of literature has documented poor outcomes associated with cooccurring disorders (45, 46), including: poor employment, family, and social outcomes (47); aggressive or antisocial behavior, criminal history involvement, recidivism, and selfharm (48, 49); relapse of substance use (48) or dependence (50, 51);…”
BackgroundJobe, L. B., Mårtensson, S., & Düring, S. W. (2023) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2023.2277820 · Cited by 7
“Off-label prescriptions can be warranted, although they should be avoided in adult populations [14,25].”
BackgroundThe Effect of Empathy on Stigma Toward Students With Substance Use Disorders in College Settings
Tu, W., Watts, J., Yang, C., Li, Q., Umucu, E., & Marini, I. (2019) · Journal of Applied Rehabilitation Counseling · doi:10.1891/0047-2220.50.4.311 · Cited by 7
Spencer, L. P., Addison, M. T., Alderson, H., McGovern, W., McGovern, R., Kaner, E., & O'Donnell, A. J. (2021) · Substance Abuse Research and Treatment · doi:10.1177/11782218211060852 · Cited by 19
The role of brain creatine in behavioral health conditions
Han, E. S., Yancey, J. R., Yurgelun-Todd, D. A., Kondo, D. G., Boxer, D., & Renshaw, P. F. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1667639 · Cited by 6
Santos, J., Camplain, C., Pollitt, A. M., & Baldwin, J. A. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13939 · Cited by 5
Ware, O. D., Zerden, L. D. S., Duron, J. F., Xu, Y., McCarthy, L. P., Verbiest, S., Afkinich, J., Brown, Q. L., Williams, D. Y., & Goings, T. C. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1340480 · Cited by 6
Managing Adult Attention-Deficit/Hyperactivity Disorder With Comorbid Substance Use Disorder
Ward, B., Bahji, A., & Crockford, D. (2022) · Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000160 · Cited by 3
Psychopathy is a neglected public health problem
Chinchilla, M. A., Reidy, D. E., & Kosson, D. S. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1657080 · Cited by 3
Long-acting injectable buprenorphine in the real world: case report on dual disorders
Palma-Álvarez, R. F., Ortega‐Hernández, G., Roch-Santed, M., Ramos‐Quiroga, J. A., & Grau‐López, L. (2024) · Journal of Addictive Diseases · doi:10.1080/10550887.2024.2354566 · Cited by 3
Managing treatment-resistant depression with comorbid substance use disorders
Stubbs, K. R., Bezooyen, J. V., & Tang, Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00031-1 · Cited by 3
Stone, B. M. (2024) · Substance Use & Misuse · doi:10.1080/10826084.2023.2280592 · Cited by 4
“…(Reed & Rountree, 1997; Studer et al., 2014), poverty (Gibbs et al., 2018; Thompson et al., 2013), psychopathology (Groenman et al., 2017; Iqbal et al., 2019), stress or grief (Chaplin et al., 2018; Parisi et al., 2019), childhood maltreatment (Cicchetti & Handley, 2019; Simpson &…”
BackgroundAttention Deficit Hyperactivity Disorder in Adults: From Research to Clinical Practice
Asherson, P. J., Balázs, J., Bitter, I., Carpentier, P. J., Jaeschke, R., Mohr, P., Ramos‐Quiroga, J. A., Rossi, P. D., Semerci, B., & Kooij, J. J. S. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009067287.010 · Cited by 4
Treating Comorbid Major Depressive Disorder and Substance Use Disorder
Glasner, S. V., & Eastlick, M. (2024) · CBT: science into practice · doi:10.1007/978-3-031-62971-6_4 · Cited by 2
Harris, U., Andersson, A., Plessen, V., & Hjelm, M. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12770-1 · Cited by 2
“Psychiatric conditions, harmful use, and addiction frequently cooccur in this group, indicating the need for more comprehensive treatment interventions [8].”
Woodhead, E. L., Ilgen, M. A., & Timko, C. (2023) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2023.209094 · Cited by 3
Alcohol and Drug Use Disorders
Baca-Atlas, M., Baca-Atlas, S. N., & Fedoriw, K. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-29171-5_6 · Cited by 1
Lawrence, R. E., Bernstein, A., Jaffe, C., Zhao, Y., Wang, Y., & Goldberg, T. E. (2024) · Journal of Dual Diagnosis · doi:10.1080/15504263.2024.2377100 · Cited by 5
Navigating the Intersection of Technology and Depression Precision Medicine
Irmak-Yazicioglu, M. B., & Arslan, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-981-97-4402-2_20 · Cited by 1
Stone, B. M. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01382-1 · Cited by 1
“…has identified several predisposing factors to SUDs, ranging from interpersonal conflict (Studer et al., 2014) to economic hardships, such as poverty and unemployment (Gibbs et al., 2018; Thompson et al., 2013), compounded by a myriad of psychopathology (Groenman et al., 2017; Iqbal et al., 2019).”
Oni, O. A., Karim, A., Kriz, C. R., Burgess, D. M., & Bruce, J. M. (2025) · Advances in Dual Diagnosis · doi:10.1108/add-05-2024-0007 · Cited by 1
Hicks, B. M., Price, A. M., Whittington, B. J., Goldman, P., & Ilgen, M. A. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113323 · Cited by 2
Harrison, A. L., Connealy, N. T., & Dulisse, B. (2026) · Police Quarterly · doi:10.1177/10986111261431303
“By extension, it is known that PMI often suffer from co-occurring disorders such as substance (ab)use (Iqbal et al., 2019) and other situational factors such as homelessness, veteran status, joblessness, low socioeconomic status, and family/domestic disturbances (Draine et al., 2002); the…”
Progress and Future: Meeting the Needs of the Nation’s Substance Use Crisis
Welsh, J. W., & Suzuki, J. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20190002
Aliemuddin, M., Kamran, M. Z., Akbar, Z., Tabassum, A. S., & Salim, F. (2021) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v71isuppl-1.2529
SOSNOSKI, O. K. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/2pef5
“Golden Shot” in the Treatment and Diagnosis of Schizophrenia: Psychiatrists or Neuroscientists?
Dubatova, I. V., Antsyborov, L. A., Хейгетян, А. В., & Antsyborov, A. V. (2021) · Interactive science · doi:10.21661/r-555399
Alcohol, Substance Use Disorders and Mental Health: Resources for U.S. Veterans
Faltinek, A. (2022) · Alcoholism Treatment Quarterly · doi:10.1080/07347324.2022.2074813
Patients with Substance Use Disorders and Dual Diagnoses
Brant, J. M., & Edwards, T. (2021) · doi:10.1093/med/9780197559321.003.0047
Dual Diagnosis: Substance Use Disorders and Co-Occurring Psychiatric Illnesses
Kolla, B. P., Mansukhani, M. P., & Loukianova, L. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95702-1.00098-1
Co-occurring Disorders: Mental Health and Alcohol Use
Romano, N., & Luba, R. R. (2024) · Psychiatry update · doi:10.1007/978-3-031-73553-0_3 · Cited by 1
Saleh, H. Y., Hasan, H. A., & Kadhim, G. N. (2025) · European Journal of Theoretical and Applied Sciences · doi:10.59324/ejtas.2025.3(2).23
Minor, T. D., Backs, A., Lu, W., Gao, N., Oursler, J. D., Beninato, J., Choi, J., Srijeyanthan, J., DeMasi, M., & Robinson, M. (2025) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20250313-02
Pham, H., Lin, C., Nguyen, D. B., Mooney, L. J., Giang, L. M., SHOPTAW, S. J., Truong, H. V., & Hser, Y. (2025) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-025-01616-w
“Managing both conditions is complex as symptoms can mask or exacerbate each other, complicating diagnosis and care (Iqbal et al., 2019).”
Rafeemanesh, E., Fathi, H. R., Talaeı, A., Rad, N. T., & Khodadadian, M. Z. (2025) · international journal high risk behaviors & addiction · doi:10.5812/ijhrba-161718
Inusah, A. S., Wu, M., Babyak, Z., Li, X., & Shan, Q. (2026) · medRxiv · doi:10.64898/2026.01.28.26344935
Kim, H. K., Beyraghi, N., Buckley, L., Hauck, T. S., Tang, V. M., & Kaduri, P. (2026) · The Canadian Journal of Psychiatry · doi:10.1177/07067437261428933
Gu, E. Y., Irvine, N. M., Miller, M. J., Ramirez, E., Santaella-Tenorio, J., Lippincott, T., Bogenschutz, M. P., Bunting, A. M., Meacham, M. C., & Krawczyk, N. (2026) · Journal of Psychedelic Studies · doi:10.1556/2054.2026.00487
Not bipolar but under-treated: How high-dose methadone rewrote the clinical narrative
Carbone, M. G., Gastaldello, G., Mazzetto, L., Bellini, A., Rizzato, R., Miccichè, R., Tripodi, B., Tagliarini, C., Rocca, F. D., & Maremmani, A. G. I. (2025) · Heroin addiction and related clinical problems · doi:10.62401/2531-4122-2025-32
McCormick-Cisse, M. N., Homish, D. L., Haney, A. M., Knapp, K. S., Kulak, J. A., Kahn, L. S., & Homish, G. G. (2026) · Criminal Justice and Behavior · doi:10.1177/00938548261449810
“Tailoring interventions to the specific needs of each participant class and combining pharmacological and psychotherapeutic methods could enhance program engagement in addition to QoL and RC scores (Hibbard & Chapman, 2024; Iqbal et al., 2019).”
Abimbola, U. K., Ijere, I. N., Nwaoru, C. R., Iloma, D. O., & Okoli, E. S. (2026) · Journal of Substance Use and Addiction Treatment · doi:10.1016/j.josat.2026.210096
Hjelm, M., Plessen, V., Andersson, A., & Harris, U. (2026) · BMC Health Services Research · doi:10.1186/s12913-026-15602-y
“Psychiatric disorders, harmful substance use, and addiction commonly co-occur, further increasing the need for comprehensive and coordinated treat-ment approaches [5].”
Metadata
- Authors
- Iqbal, M. N., Levin, C. J., & Levin, F. R.
- Affiliations
- New York State Psychiatric Institute (US)
- Venue
- Focus
- Published
- 2019-04
- Volume
- 17
- Issue
- 2
- Pages
- 88-97
- ISSN
- 1541-4094 (ISSN-L)
- 1541-4108
- PMC
- PMC6526999
- OpenAlex
- W2938661501
- Cited by
- 66
- References
- 169
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 14 · 2023: 10 · 2022: 5 · 2021: 11 · 2020: 4 · 2019: 2
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- FOCUS The Journal of Lifelong Learning in Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (K24DA029647, T32DA007294)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- substance use disorders, co-occurring disorders, dual diagnosis, major depressive disorder, anxiety disorders, attention deficit hyperactivity disorder, pharmacotherapy, psychotherapy, topiramate, ketamine, non-invasive brain stimulation, deep brain stimulation, abstinence, comorbidities
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.